Novus Biologicals Competitors and Similar CompaniesClear all

Novus Biologicals's competitors and similar companies include Genentech, Ipsen and BioMarin Pharmaceutical.

	Novus Biologicals Novus Biologicals is a company developing and marketing products for the life sciences.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Ipsen Ipsen is a biopharmaceutical company.	BioMarin Pharmaceutical BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.
Founding Date	Founding Date 1996	Founding Date 1976	Founding Date 1929	Founding Date 1997
Type	Type Subsidiary	Type Subsidiary	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Centennial, US HQ Toronto, CA Pune, IN Seongnam Si, KR Abingdon, GB Centennial, US	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations San Rafael, US HQ Martínez, AR Crows Nest, AU Sao Paulo, BR Bogotá, CO Kronberg Im Taunus, DE Wanchai, HK see more
Employees	Employees 42	Employees 18,077	Employees 5,358	Employees 3,0015% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 10.2 b	Valuation ($) 13.3 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €3.7b (FY, 2025)	Revenue (est.) $3.2b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €659.1m (FY, 2025)	Cost of goods $717.4m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €3.3b (FY, 2025)	Gross profit $2.5b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income €445.1m (FY, 2025)	Net income $348.9m (FY, 2025)
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 41 (Jul, 2025)	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)